Sun Pharmaceutical Industries Ltd. announced that US FDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) for generic version of Plavix, clopidogrel tablets USP.

These generic clopidogrel tablets USP, 75 mg are therapeutic equivalents of Sanofi Aventis’s Plavix tablets.

Clopidogrel tablets USP have annual sale of approximately $ 6 billion in the US.

Clopidogrel tablets USP are indicated for the treatment of acute coronary syndrome, recent Myocardial Infarction (MI), recent stroke, or established peripheral arterial disease.

Plavix is a registered trademark of Sanofi Aventis US. (Sanofi)

Sun Pharmaceutical Industries Ltd. is an international, integrated, speciality pharmaceutical company and it manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.